Showing results (161-170 of 221) with videos related to
Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.The Journal of Urology|February 1, 1989
Congenital pelvic arteriovenous malformation with massive prostatic hemorrhage: a case reportM H Siegelbaum, A M Samaha, W L Gerber, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasLia Gore, Mace L Rothenberg, Cindy L O'Bryant, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|October 26, 2018
Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) InhibitionDebapriya Basu, Lesley-Ann Huggins, Diego Scerbo, et al.Cancer Chemotherapy and Pharmacology|November 9, 2006
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumorsA C Lockhart, R Bukowski, M L Rothenberg, et al.Cancer Medicine|January 24, 2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesKenichi Sugihara, Atsushi Ohtsu, Yasuhiro Shimada, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2009
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupElizabeth Poplin, Yang Feng, Jordan Berlin, et al.Investigational New Drugs|October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumorsAndrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.Investigational New Drugs|September 22, 2010
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabineLaura W Goff, Al B Benson, Patricia M LoRusso, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 studyKenneth R Hande, Anne Hagey, Jordan Berlin, et al.Pageof 23